

### **AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions and listings of claims in the application:

Claims 1-15 (cancelled).


16. (Currently amended) An isolated antibody that binds to an extracellular portion of a Breast Cancer Resistance Protein (BCRP) selected from the group consisting of human or murine BCRP; wherein the extracellular portion of the BCRP is in its natural conformation; wherein the antibody binds to living MCF-7 or 3T3 cells expressing BCRP on their surface; ~~and~~ wherein the antibody ~~fails to~~ does not bind to living MCF-7 cells that do not express BCRP on their surface; and wherein the antibody does not bind to denatured BCRP.

Claims 17-21 (cancelled).

22. (Previously presented) The isolated antibody of claim 16 wherein the isolated antibody is monoclonal.
23. (Previously presented) The isolated antibody of claim 16 wherein the isolated antibody is chimeric.
24. (Previously presented) The isolated antibody of claim 23 wherein the antibody is humanized.

Claims 25-28 (cancelled).

29. (Previously presented) The isolated antibody of claim 16, operably attached to a detectable label.
30. (Previously presented) An immunodetection kit comprising, in suitable container means, the antibody according to claim 16 and an immunodetection reagent.

- {W:\02427\1203347us2\00804940.DOC |  }